fbpx
Medical Innovation Exchange

FDA’s Califf backs limited use of single-arm trials, but says regulatory pathways for some cancers should 'move into a new phase'

https://www.fiercebiotech.com/biotech/fdas-califf-says-many-cases-regulatory-pathways-cancer-should-move-new-phase

Leave a Comment

Your email address will not be published.

Leave the field below empty!

This site uses Akismet to reduce spam. Learn how your comment data is processed.